Last reviewed · How we verify

Insulin Detemir mixed with RAI injection

Montefiore Medical Center · FDA-approved active Small molecule

Insulin Detemir mixed with RAI injection is a Basal insulin analog Small molecule drug developed by Montefiore Medical Center. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Insulin detemir provides basal insulin replacement by binding to the insulin receptor, while RAI (radioactive iodine) component is unclear in this context as RAI is typically used for thyroid ablation, not diabetes management.

Insulin detemir provides basal insulin replacement by binding to the insulin receptor, while RAI (radioactive iodine) component is unclear in this context as RAI is typically used for thyroid ablation, not diabetes management. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameInsulin Detemir mixed with RAI injection
SponsorMontefiore Medical Center
Drug classBasal insulin analog
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Insulin detemir is a long-acting basal insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues. The addition of RAI (radioactive iodine) to an insulin injection is highly unusual and not a standard pharmaceutical formulation; RAI is typically administered orally or as a separate therapeutic agent for thyroid conditions, not mixed with insulin injections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Insulin Detemir mixed with RAI injection

What is Insulin Detemir mixed with RAI injection?

Insulin Detemir mixed with RAI injection is a Basal insulin analog drug developed by Montefiore Medical Center, indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

How does Insulin Detemir mixed with RAI injection work?

Insulin detemir provides basal insulin replacement by binding to the insulin receptor, while RAI (radioactive iodine) component is unclear in this context as RAI is typically used for thyroid ablation, not diabetes management.

What is Insulin Detemir mixed with RAI injection used for?

Insulin Detemir mixed with RAI injection is indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Who makes Insulin Detemir mixed with RAI injection?

Insulin Detemir mixed with RAI injection is developed and marketed by Montefiore Medical Center (see full Montefiore Medical Center pipeline at /company/montefiore-medical-center).

What drug class is Insulin Detemir mixed with RAI injection in?

Insulin Detemir mixed with RAI injection belongs to the Basal insulin analog class. See all Basal insulin analog drugs at /class/basal-insulin-analog.

What development phase is Insulin Detemir mixed with RAI injection in?

Insulin Detemir mixed with RAI injection is FDA-approved (marketed).

What are the side effects of Insulin Detemir mixed with RAI injection?

Common side effects of Insulin Detemir mixed with RAI injection include Hypoglycemia, Injection site reactions, Weight gain, Lipodystrophy.

What does Insulin Detemir mixed with RAI injection target?

Insulin Detemir mixed with RAI injection targets Insulin receptor and is a Basal insulin analog.

Related